Compare, Analyse Glenmark Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GLENMARK PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
ADCOCK INGRAM
Jun-14
GLENMARK PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs712349-   
Low Rs484252-   
Sales per share (Unadj.) Rs349.6104.0-  
Earnings per share (Unadj.) Rs32.8-26.2-  
Cash flow per share (Unadj.) Rs44.3-21.7-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs198.681.6-  
Shares outstanding (eoy) m282.17168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.72.9 59.1%   
Avg P/E ratio x18.2-11.5 -158.8%  
P/CF ratio (eoy) x13.5-13.9 -97.3%  
Price / Book Value ratio x3.03.7 81.6%  
Dividend payout %6.10-   
Avg Mkt Cap Rs m168,62550,764 332.2%   
No. of employees `00012.04.3 280.4%   
Total wages/salary Rs m20,5613,186 645.3%   
Avg. sales/employee Rs Th8,196.04,086.8 200.5%   
Avg. wages/employee Rs Th1,708.1742.1 230.2%   
Avg. net profit/employee Rs Th768.5-1,029.8 -74.6%   
INCOME DATA
Net Sales Rs m98,65517,545 562.3%  
Other income Rs m2,081123 1,694.1%   
Total revenues Rs m100,73617,668 570.2%   
Gross profit Rs m15,858-3,040 -521.6%  
Depreciation Rs m3,259757 430.4%   
Interest Rs m3,346475 704.0%   
Profit before tax Rs m11,335-4,150 -273.1%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,6720-   
Tax Rs m3,756259 1,448.6%   
Profit after tax Rs m9,250-4,421 -209.2%  
Gross profit margin %16.1-17.3 -92.8%  
Effective tax rate %33.1-6.2 -530.4%   
Net profit margin %9.4-25.2 -37.2%  
BALANCE SHEET DATA
Current assets Rs m66,96812,850 521.1%   
Current liabilities Rs m40,2117,230 556.2%   
Net working cap to sales %27.132.0 84.7%  
Current ratio x1.71.8 93.7%  
Inventory Days Days83111 75.1%  
Debtors Days Days81124 65.5%  
Net fixed assets Rs m33,3227,490 444.9%   
Share capital Rs m28281 346.4%   
"Free" reserves Rs m55,7700-   
Net worth Rs m56,05213,771 407.0%   
Long term debt Rs m35,7384,839 738.5%   
Total assets Rs m132,88826,014 510.8%  
Interest coverage x4.4-7.7 -56.7%   
Debt to equity ratio x0.60.4 181.4%  
Sales to assets ratio x0.70.7 110.1%   
Return on assets %9.5-15.2 -62.5%  
Return on equity %16.5-32.1 -51.4%  
Return on capital %17.8-19.8 -89.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m40,1400-   
CASH FLOW
From Operations Rs m13,2421,498 884.2%  
From Investments Rs m-6,990-460 1,520.1%  
From Financial Activity Rs m-7,3874,392 -168.2%  
Net Cashflow Rs m-2,9715,430 -54.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.82 Rs / ZAR

Compare GLENMARK PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare GLENMARK PHARMA With: FRESENIUS KABI ONCO.  DR. DATSONS LABS  TORRENT PHARMA  AUROBINDO PHARMA  FULFORD INDIA  



Today's Market

Sensex Gains 300 Points; Hero MotoCorp & Maruti Suzuki Top Gainers(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Signs of easing trade tension between the US and China provided some respite to investors globally.

Related Views On News

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound? (The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks (Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market (The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 15, 2019 12:41 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - PFIZER COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS